Lv5
1040 积分 2024-09-29 加入
Practical Considerations in Determining Adversity and the No-Observed-Adverse-Effect-Level (NOAEL) in Nonclinical Safety Studies: Challenges, Perspectives and Case Studies
7小时前
已完结
An Industry Perspective on Key Considerations for the ICH S13 Guidance: Nonclinical Safety Evaluations of Oligonucleotide-Based Therapeutics
7小时前
已完结
Translational Challenges From Nonclinical to Clinical Program: Case Study Examples
10小时前
已完结
Impurities in Active Pharmaceutical Ingredients and Drug Products: A Critical Review
10小时前
已完结
Safety assessment of drug impurities for patient safety: A comprehensive review
10小时前
已完结
Safety assessment of antibody-drug conjugates: Nonclinical toxicology, non-active ingredients, and environmental risk considerations
20天前
已完结
PI3K Inhibitors: Understanding Toxicity Mechanisms and Management
22天前
已关闭
Historical Control Background Incidence of Spontaneous Nonneoplastic Lesions of Sprague Dawley Rats in 104-Week Carcinogenicity Studies
23天前
已完结
Discovery and research progress of CDK8 inhibitors
28天前
已完结
皖公网安备34019202002308
